Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

Historical Holders from Q1 2014 to Q1 2025

Symbol
KPTI on Nasdaq
CUSIP
48576U106
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
126M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
60.9M
Holdings value
$41.2M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
86
Number of buys
31
Number of sells
-40
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Adage Capital Management, L.P. 5.18% $3.93M 6.55M Adage Capital Management, L.P. Dec 31, 2024

Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 0 $0 -$189K 0
2024 Q4 60.9M $41.2M -$292K $0.68 86
2024 Q3 59.3M $49.2M -$6.33M $0.83 90
2024 Q2 67.6M $58.6M -$7.62M $0.87 115
2024 Q1 74.7M $113M +$4.83M $1.51 112
2023 Q4 73.3M $63.4M -$4.33M $0.87 116
2023 Q3 76.1M $102M -$10.7M $1.34 114
2023 Q2 80.4M $144M -$18.6M $1.79 132
2023 Q1 87.6M $340M -$32.8M $3.89 127
2022 Q4 98.4M $334M +$100M $3.40 150
2022 Q3 65M $355M -$1.86M $5.46 137
2022 Q2 67M $302M -$6.98M $4.51 142
2022 Q1 58.9M $432M +$112M $7.37 129
2021 Q4 44.1M $283M +$1.31M $6.43 134
2021 Q3 55.5M $323M -$27M $5.82 129
2021 Q2 59M $608M -$13.8M $10.32 147
2021 Q1 59.1M $621M -$47.5M $10.52 164
2020 Q4 62.6M $969M -$61.5M $15.48 160
2020 Q3 64.3M $939M -$114M $14.60 150
2020 Q2 69.7M $1.32B +$56.6M $18.94 151
2020 Q1 67.1M $1.29B +$217M $19.21 133
2019 Q4 59M $1.13B -$54.7M $19.17 146
2019 Q3 58.5M $563M +$83.6M $9.62 105
2019 Q2 51.1M $306M +$9.7M $5.99 100
2019 Q1 51.1M $298M +$12.3M $5.84 100
2018 Q4 49.1M $460M +$67.9M $9.37 114
2018 Q3 43.3M $737M -$819K $17.03 117
2018 Q2 43.3M $735M +$217M $16.99 107
2018 Q1 30.9M $415M +$169K $13.42 89
2017 Q4 30.8M $296M +$20.1M $9.60 86
2017 Q3 28.7M $316M +$10.7M $10.98 74
2017 Q2 27.6M $250M +$6.05M $9.05 69
2017 Q1 26.8M $345M +$45.3M $12.84 79
2016 Q4 25.5M $239M +$21.2M $9.40 85
2016 Q3 23.1M $224M +$31.5M $9.73 74
2016 Q2 20M $134M -$8.39M $6.71 72
2016 Q1 21.2M $189M -$5.33M $8.92 75
2015 Q4 21.2M $281M -$26.1M $13.25 84
2015 Q3 23.5M $248M -$7.32M $10.53 88
2015 Q2 22.1M $602M +$39.3M $27.21 85
2015 Q1 20.8M $636M +$53.6M $30.61 84
2014 Q4 18.5M $691M +$48.1M $37.43 79
2014 Q3 16.7M $583M +$52.3M $34.94 69
2014 Q2 15.1M $703M +$235M $46.55 76
2014 Q1 10.1M $311M +$33.6M $30.89 59